Method development, validation and routine release testing for pharmaceutical products — designed to MHRA and EU GMP standards. Whether you are working through Phase III material, scaling up commercial release, or preparing for an MHRA inspection, we plug into your quality system without friction.
Identity, assay and content uniformity testing for finished drug products
Related substances, impurities and degradation product profiling
Dissolution, disintegration and uniformity of dosage units
Water content (Karl Fischer), residual solvents, elemental impurities
Cleaning verification samples, swabs and rinsates
Forced-degradation studies and stress testing
Method development, validation, transfer and verification
Routine batch release for IMP and commercial product
Reversed-phase, normal-phase, ion-exchange and HILIC for assay, related substances and content uniformity.
High-sensitivity quantification, structural elucidation of impurities, extractables/leachables.
Residual solvents (USP <467>, ICH Q3C) and volatile impurity profiling.
Elemental impurities to ICH Q3D, USP <232>/<233>, Ph. Eur. 2.4.20.
Identity confirmation, content assay and qualitative comparison against reference.
Coulometric and volumetric water content for solid, liquid and gas samples.
USP Apparatus 1, 2 and (where appropriate) 3/4 with auto-sampling.
Titrimetric assays, pH, conductivity, refractive index, optical rotation.
Methods, documentation and acceptance criteria are designed to align with the standards below. This describes design intent — formal accreditations are listed on the About page.
Certificate of Analysis (CoA) signed by Quality
Validated method and full method validation report (where in scope)
Method transfer protocol and report when transferring from another lab
Investigational reports (OOS, OOT, deviations) with documented root cause
Specification design recommendation aligned to ICH Q6A
Inspection-ready raw data and audit trail
Send a short scope and we'll come back with a quote and indicative timeline within one working day.